Intravitreal aflibercept 8 mg versus 2 mg in Asian patients with neovascular age-related macular degeneration: 48-week analysis of the Phase 3 PULSAR trial.
- DOI
- 10.1016/j.apjo.2026.100278
- Published
- 2026 Jan-Feb
- Container
- Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.apjo.2026.100278,
title = {Intravitreal aflibercept 8 mg versus 2 mg in Asian patients with neovascular age-related macular degeneration: 48-week analysis of the Phase 3 PULSAR trial.},
author = {Chang A and Sun X and Iida T and Lai TYY and Wong TY and Cheung CMG and Lee WK and Zhang X and Schulze A and Schmidt-Ott UM and Zhao M and Hasanbasic Z and Leal S and Chen SJ and PULSAR study investigators},
year = {2026},
journal = {Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)},
doi = {10.1016/j.apjo.2026.100278},
url = {https://doi.org/10.1016/j.apjo.2026.100278}
}RIS
TY - JOUR TI - Intravitreal aflibercept 8 mg versus 2 mg in Asian patients with neovascular age-related macular degeneration: 48-week analysis of the Phase 3 PULSAR trial. AU - Chang A AU - Sun X AU - Iida T AU - Lai TYY AU - Wong TY AU - Cheung CMG AU - Lee WK AU - Zhang X AU - Schulze A AU - Schmidt-Ott UM AU - Zhao M AU - Hasanbasic Z AU - Leal S AU - Chen SJ AU - PULSAR study investigators PY - 2026 JO - Asia-Pacific journal of ophthalmology (Philadelphia, Pa.) DO - 10.1016/j.apjo.2026.100278 UR - https://doi.org/10.1016/j.apjo.2026.100278 ER -
APA
A, C., X, S., T, I., TYY, L., TY, W., CMG, C., WK, L., X, Z., A, S., UM, S., M, Z., Z, H., S, L., SJ, C., & investigators, P. S. (2026). Intravitreal aflibercept 8 mg versus 2 mg in Asian patients with neovascular age-related macular degeneration: 48-week analysis of the Phase 3 PULSAR trial.. Asia-Pacific journal of ophthalmology (Philadelphia, Pa.). https://doi.org/10.1016/j.apjo.2026.100278
Source records
- pubmed · retrieved 2026-09-25T19:24:07.438Z